Home
Resources
Publications
Fluoroquinolones Versus Trimethoprim-Sulfamethoxazole for the Treatment of Stenotrophomonas Maltophilia Infections: A Systematic Review and Meta-Analysis

Fluoroquinolones Versus Trimethoprim-Sulfamethoxazole for the Treatment of Stenotrophomonas Maltophilia Infections: A Systematic Review and Meta-Analysis

J-H Ko, C-I Kang, P Cornejo-Juárez, K-M Yeh, C-H Wang, S Y Cho, M G Gözel, S-H Kim, P-R Hsueh, N Sekiya, Y Matsumura, D-G Lee, S-Y Cho, S Shiratori, Y-J Kim, D R Chung, K R Peck

Clin Microbiol Infect. 2019 May;25(5):546-554.

PMID: 30448331

Abstract:

Background:
Fluoroquinolones are a popular alternative to trimethoprim-sulfamethoxazole for Stenotrophomonas maltophilia infections.
Objectives:
To compare the effects of fluoroquinolones and trimethoprim-sulfamethoxazole on mortality of S. maltophilia infections.
Data sources:
PubMed and EMBASE.
Study eligibility criteria:
Clinical studies reporting mortality outcomes of S. maltophilia infections.
Participants:
Patients with clinical infections caused by S. maltophilia.
Interventions:
Fluoroquinolone monotherapy in comparison with trimethoprim-sulfamethoxazole monotherapy.
Methods:
Systematic review with meta-analysis technique.
Results:
Seven retrospective cohort and seven case-control studies were included. Three cohort studies were designed to compare the two drugs, whereas others had other purposes. A total of 663 patients were identified, 332 of which were treated with trimethoprim-sulfamethoxazole (50.1%) and 331 with fluoroquinolones (49.9%). Three cohort studies were designed to compare the effect of the two drugs, whereas the others had other purposes. Levofloxacin was most frequently used among fluoroquinolones (187/331, 56.5%), followed by ciprofloxacin (114/331, 34.4%). The overall mortality rate was 29.6%. Using pooled ORs for the mortality of each study, fluoroquinolone treatment (OR 0.62, 95% CI 0.39-0.99) was associated with survival benefit over trimethoprim-sulfamethoxazole treatment, with low heterogeneity (I2 = 18%). Specific fluoroquinolones such as ciprofloxacin (OR 0.44, 95% CI 0.17-1.12) and levofloxacin (OR 0.78, 95% CI 0.48-1.26) did not show a significant difference in comparison with trimethoprim-sulfamethoxazole. In the sub-group analyses of adult and bacteraemic patients, significant differences in mortality were not observed between fluoroquinolones and trimethoprim-sulfamethoxazole.
Conclusions:
Based on a meta-analysis of non-randomized studies, fluoroquinolones demonstrated comparable effects on mortality of S. maltophilia infection to trimethoprim-sulfamethoxazole, supporting the use of fluoroquinolones in clinical S. maltophilia infections. Although the pooled analysis of overall studies favoured fluoroquinolones over trimethoprim-sulfamethoxazole, the studies included were observational, and sub-group analyses of certain fluoroquinolone agents did not show statistical differences with trimethoprim-sulfamethoxazole. Randomized clinical studies are needed to address these issues.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP119691757	Sulfamethoxazole N4-glucoside		119691-75-7	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: